WuXi XDC, a leading global Contract Research, Development and Manufacturing Organization (CRDMO) focused on the ADC and broader bioconjugate market, and Boostimmune, a biotech company dedicated to developing next-generation anti-cancer therapies modulating the tumor immune microenvironment and ADCs to novel targets, announced that they have signed a Memorandum of Understanding (MOU) for comprehensive, integrated discovery services for Boostimmune's pipeline.

Under the collaboration, Boostimmune will have access to WuXi XDC's fully integrated, one-stop bioconjugate platform and extensive expertise in industry-leading discovery capabilities, with WuXi XDC providing end-to-end services to support Boostimmune's discovery of novel bioconjugates.

Dr. Gwanghee Lee, Co-founder and CEO of Boostimmune, commented, "Boostimmune is focused on answering urgent unmet clinical needs and dedicated to providing patients around the world with high-quality, innovative therapies. Accessing WuXi XDC's leading bioconjugate platform and in-depth industry know-how will afford exciting opportunities for us to explore novel ADCs and other bioconjugates that could become transformative therapeutics."

Dr. Jimmy Li, CEO of WuXi XDC, commented, "We look forward to supporting Boostimmune with our state-of-the-art conjugation technologies and high-quality services. Our fully integrated, one-stop platform will accelerate the ADC discovery timeline and enable Boostimmune to advance its innovative pipeline. As a global CRDMO, we aim to continually enhance our platform and help propel the growth of the bioconjugate industry for the benefit of patients worldwide."